Keywords: Gilead, GSK, GlaxoSmithKline, hepatitis B, Viread
Gilead and GlaxoSmithKline to commercialize Viread for chronic hepatitis B in key Asian countries; update on Avodart
Article | 26 November 2009
The USA’s Gilead Sciences and UK drug giant GlaxoSmithKline have signed a licensing agreement to commercialize the former’s Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. The companies’ combined commercialization activities will expand access to Viread for the treatment of HBV, once approved, to patients in Asia where the prevalence in most countries is more than 8%.
Under the deal, Gilead will retain exclusive rights for commercializing Viread for HBV in Hong Kong, Singapore, South Korea and Taiwan. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
